What's new

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024

Mar 13, 2025 - 16:11
 0
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024
Read More

Tags:

Previous Article

Hospitality Asset Managers Association (HAMA) Names Annual Student Case Competit...

Next Article

Surfside rides wave of success with spirits-forward cocktails: ‘We want to be th...

Related Posts

P/87/2010

P/87/2010

Feb 9, 2025  0

Marketing authorisation application (MAA) - pre-submiss...

Feb 24, 2025  0

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0